HLX-0553

HLX-0553 is a preclinical drug candidate being developed by Healx for the treatment of Angelman Syndrome. It was identified using Healx's AI-powered drug discovery platform, Healnet, which integrates pharmacological, genomic, and clinical data to identify novel treatments for rare diseases. Angelman Syndrome is a rare neurogenetic disorder characterized by severe intellectual disability, sleep disturbances, seizures, and movement disorders, typically caused by a deficiency in the UBE3A protein. HLX-0553 is currently undergoing preclinical evaluation to assess its potential to address the underlying symptoms or pathology of the condition.